G01N 2333/5421
Il-8
G01N2333/5421 (Il-8) appears on 77 US grants and 196 published applications in this corpus.
Search patents in G01N- Granted patents
- 77
- Published applications
- 196
- Assignees
- 140
- Inventors
- 447
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 4 |
| 2011 | 0 | 7 |
| 2012 | 1 | 5 |
| 2013 | 3 | 4 |
| 2014 | 2 | 8 |
| 2015 | 0 | 12 |
| 2016 | 4 | 20 |
| 2017 | 6 | 17 |
| 2018 | 11 | 11 |
| 2019 | 11 | 11 |
| 2020 | 5 | 13 |
| 2021 | 5 | 12 |
| 2022 | 8 | 16 |
| 2023 | 4 | 15 |
| 2024 | 2 | 14 |
| 2025 | 6 | 18 |
| 2026 | 8 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treating an autoimmune disease with a human interleukin-3 (IL-3)-diphtheria toxin conjugate (DT-IL3)14 Jul 2026US 12,678,485 B2Stemline Therapeautics, Inc.
- Cytokine-based therapies and methods30 Jun 2026US 12,668,627 B2Reverb Therapeutics, Inc.
- Biomarkers of early osteoarthritis16 Jun 2026US 12,656,343 B2CD Diagnostics, Inc.
- Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status14 Apr 2026US 12,601,747 B2Bio-Rad Laboratories, Inc.
- Methods for the prediction, prognosis, and/or diagnosis of an inflammatory response associated with schizophrenia7 Apr 2026US 12,596,126 B2
- Novel cytokine-based therapies and methods17 Sep 2026US 2026/0274943 A1Reverb Therapeutics, Inc.
- CXCL8 Binding Nucleic Acids30 Jul 2026US 2026/0218203 A1APTARION biotech AG
- Method for the detection of cancer16 Jul 2026US 2026/0202420 A1Belgian Volition SPRL
- Biomarkers in ex vivo lung perfusion (evlp) perfusate9 Jul 2026US 2026/0194536 A1University Health Network
- Activation-dependent immune dysfunction traits enable identification of prodromal Parkinson's28 May 2026US 2026/0146997 A1
Most cited
By later US patents
- Diagnosis of sepsis35US 7,767,395 B2Becton, Dickinson and Company · 2010
- Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof17US 10,859,574 B2MeMed Diagnostics Ltd. · 2020
- Methods for prediction of anti-TNFα drug levels and autoantibody formation12US 10,571,467 B2Prometheus Biosiences, Inc. · 2020
- Diagnosis of urothelial cancer11US 10,168,331 B2Randox Laboratories Limited · 2019
- Atypical hemolytic uremic syndrome (AHUS) biomarker proteins11US 9,494,601 B2Alexion Pharmaceuticals, Inc. · 2016